Caplin Point Laboratories Limited (CAPLIPOINT)

Loading page…

Caplin Point Laboratories Limited (CAPLIPOINT) · mywealthgrid

About

Caplin Point Laboratories manufactures pharmaceuticals with consolidated quarterly revenues around ₹610 Cr and operating margin of 34.79%. Market cap ₹18,851.8 Cr places it as mid-cap player in Indian pharma. Demonstrates consistent profitability and regular dividend distributions.

Founded: 1990
Face value: ₹2

Market cap

₹20,002 Cr

P/E

30.1×

P/B

5.6×

Dividend yield

0.3%

ROE

19.9%

ROCE

24.5%

Debt / equity

OPM

34.8%

EPS (TTM)

₹87.5

Book value

₹471.9

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

PE of 28.33 is elevated for sector; leaves limited margin of safety if growth fails to exceed recent ~2% QoQ pace
Standalone OPM 43-48% vs consolidated 34-35% (9-13 point gap) warrants clarification—may reflect consolidated drag, different business mix, or integration costs
Quarterly revenue growth at ~2% recently appears modest; verify if driven by end-market softness, pricing pressure, or portfolio mix shifts
Sector risks (generic competition, pricing controls, API supply constraints) require verification for this company's specific product exposure

Generated analysis · source review pending

Growth drivers

OPM of 34.79% on quarterly revenue base of ₹610 Cr means material absolute profit from incremental sales; if growth accelerates beyond recent ~2% pace, profit flows through at margin rate
Zero debt (D/E 0) provides capacity for organic capex or acquisitions; verify management's stated capital allocation priorities and announced growth investments
ROE of 19.92% indicates efficient capital deployment; retained earnings reinvested in growth could sustain returns; verify pipeline and market positioning

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹2,631.9-4.1%1Y

Quick read

rule-based

Pros

+Strong return on equity of 21.2% (3-yr avg)
+High return on capital employed of 25.5%
+Healthy operating margin of 34.8%
+Profit CAGR of 21.5% over the last 5 years
+Revenue CAGR of 15.6% over the last 5 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 923.7×
+High promoter holding of 70.6% with no pledge

Cons

−Low dividend payout of 9.1% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

65/100

Business quality: 85

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY SMALLCAP 250 NIFTY MIDSMALLCAP 400 NIFTY 500 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2018	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	540	1,061	1,269	1,467	1,694	1,937	2,187
COGS	238	472	558	663	724	771	866
Gross profit	302	590	712	804	970	1,167	1,322
	107	261	317	362	418	520	561
	195	329	395	441	551	647	761
OPM %	36.1%	31%	31.1%	30.1%	32.6%	33.4%	34.8%
Depreciation	19	37	47	45	53	66	73
Interest	0	2	1	1	1	1	1
	13	24	39	56	67	96	116
Profit before tax	188	314	386	451	564	677	803
Tax	44	62	77	74	103	136	153
Tax %	23.2%	19.8%	20.1%	16.5%	18.3%	20.1%	19.1%
	145	251	308	377	461	541	650
PAT margin %	26.8%	23.7%	24.3%	25.7%	27.2%	27.9%	29.7%
EPS (₹)	19.3	32	39.6	49.6	60.2	70.6	84.4
EPS adjusted (₹)	19.2	32	40.7	49.6	60.2	74.1	84.4
	10.4%	4.7%	8.8%	9.1%	7.5%	7.8%	8.3%
Annual report	Annual report for Mar 2018	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	15	15	15	15	15	15	15	15	15	15
Reserves	113	120	210	933	1,171	1,469	1,865	2,301	2,835	3,571
Minority interest	—	—	—	—	18	26	27	31	36	44
	1	1	0	36	17	1	3	1	1	1
	138	131	133	141	143	226	281	349	322	414
Total equity & liabilities	267	267	358	1,126	1,364	1,736	2,191	2,697	3,209	4,045
	144	144	152	271	305	287	278	451	542	580
CWIP	0	0	3	20	14	15	220	117	139	209
Investments	5	5	18	61	11	89	230	376	590	859
	118	118	185	774	1,033	1,345	1,463	1,754	1,937	2,398
Total assets	267	267	358	1,126	1,364	1,736	2,191	2,697	3,209	4,045

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.

Source XBRL ↗

Latest reported period · 31 Mar 2026 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities	Capital employed	ROCE %
Rest of the World	1,733.79	631.2	1,918.28	332.52	1,585.76	39.8
USA	453.4	56.05

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2018	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	55.9%	55.6%	56.1%	54.8%	57.3%	60.2%	60.4%
EBITDA margin %	36.1%	31%	31.1%	30.1%	32.6%	33.4%	34.8%
EBIT margin %	32.6%	27.5%	27.4%	27%	29.4%	30%	31.5%
PAT margin %	26.8%	23.7%	24.3%	25.7%	27.2%	27.9%	29.7%
Working capital
Receivable days	22	96	91	98	117	119	138
Inventory days	34	139	149	159	183	159	181
Payable days	120	68	102	90	106	103	125
NWC days	-64	166	138	166	194	175	194
Leverage
Current ratio	—	7.1	6.25	5.8	5.72	6.97	6.7
Debt to EBITDA	0	0.05	0	0.01	0	0	0
Debt to equity	0	0.01	0	0	0	0	0
Interest coverage	3,140.7	198.2	552.2	579.6	724.3	1,110.5	923.7
Asset turnover	1.51	0.78	0.73	0.67	0.63	0.6	0.54
Return ratios
Return on assets %	40.4%	18.4%	17.8%	17.2%	17.1%	16.9%	16.1%
Return on capital employed %	—	25.8%	28.1%	26.2%	26.3%	25.7%	24.5%
Return on equity %	64.4%	21.2%	20.8%	20%	19.9%	19%	18.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	70.63%	70.62%	70.62%	70.56%	70.56%	70.56%	70.56%	70.56%	70.57%	70.57%	70.57%	70.57%
	3.09%	2.85%	3.34%	3.37%	3.7%	4.86%	5.73%	6.17%	6.51%	6.59%	6.15%	5.75%
	0.2%	0.43%	1.09%	1.49%	1.84%	2.11%	2.01%	2.22%	2.1%	2.05%	2.14%	2.49%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	26.08%	26.1%	24.95%	24.58%	23.9%	22.47%	21.7%	21.05%	20.82%	20.79%	21.14%	21.19%
No. of shareholders	—	—	—	—	—	—	—	—	93,753	93,705	93,896	94,385

Promoter holding down 0.06 percentage points since Sep 2023.

6 deals · 9 Sept 2021 – 26 Aug 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
26 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	3,96,355	₹1,901.28	₹75.36 Cr
26 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	3,96,355	₹1,899.60	₹75.29 Cr
19 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	4,44,478	₹1,763.58	₹78.39 Cr
19 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	4,44,478	₹1,761.72	₹78.30 Cr
9 Sept 2021	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	3,81,306	₹908.54	₹34.64 Cr
9 Sept 2021	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	3,81,306	₹908.19	₹34.63 Cr

1–6 of 6

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. C C PaarthipanNon-Executive - Non Independent Director-Chairperson
D MuralidharanChief Financial Officer
Mr. Sridhar GanesanExecutive Director-MD
Mr. R NagendranNon-Executive - Independent Director
Vivek SiddharthChief Operating Officer
Mr. S DeenadayalanNon-Executive - Independent Director
Mr. Ranganathan VijayaraghavanNon-Executive - Independent Director
Mr. Ashok PartheebanNon-Executive - Non Independent Director
Mr. K C JohnNon-Executive - Independent Director
Mr. Vivek PartheebanNon-Executive - Non Independent Director
Ms. Susan MathewNon-Executive - Independent Director

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 10 fund houses

Held by these funds

0.14%

of the company's equity

All mutual funds

2.03%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

27 schemes · 10 fund houses

		Shares
Nifty Smallcap 250 Index Fund	Nippon India Mutual Fund	31,780	8	0.23%	0.042%	+388
Small Cap Fund	Quantum Mutual Fund	16,572	4.17	1.57%	0.022%	-0
Nifty Smallcap 250 Index Fund	SBI Mutual Fund	16,151	4.07	0.23%	0.021%	+181
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	11,708	2.95	0.23%	0.015%	+106
Nifty Smallcap 250 Index Fund	ICICI Prudential Mutual Fund	7,118	1.79	0.23%	0.009%	+139
(LIVE SCHEMES)	ITI Mutual Fund	6,702	1.69	0.61%	0.009%	+1,018
Nifty 500 Equal Weight Index Fund	Nippon India Mutual Fund	3,956	1	0.19%	0.005%	+2
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	3,179	0.8	0.03%	0.004%	+109

1–8 of 27

1 / 4

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Investor Presentation and earnings call

Aug 2026Transcript AI SummaryPPTREC
May 2026Transcript AI SummaryPPTREC

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

14 announcementsExport CSV

28 Sept 2026, 5:05 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

Loading announcements…

Ratio	Mar 2018	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	55.9%	55.6%	56.1%	54.8%	57.3%	60.2%	60.4%
EBITDA margin %	36.1%	31%	31.1%	30.1%	32.6%	33.4%	34.8%
EBIT margin %	32.6%	27.5%	27.4%	27%	29.4%	30%	31.5%
PAT margin %	26.8%	23.7%	24.3%	25.7%	27.2%	27.9%	29.7%
Working capital
Receivable days	22	96	91	98	117	119	138
Inventory days	34	139	149	159	183	159	181
Payable days	120	68	102	90	106	103	125
NWC days	-64	166	138	166	194	175	194
Leverage
Current ratio	—	7.1	6.25	5.8	5.72	6.97	6.7
Debt to EBITDA	0	0.05	0	0.01	0	0	0
Debt to equity	0	0.01	0	0	0	0	0
Interest coverage	3,140.7	198.2	552.2	579.6	724.3	1,110.5	923.7
Asset turnover	1.51	0.78	0.73	0.67	0.63	0.6	0.54
Return ratios
Return on assets %	40.4%	18.4%	17.8%	17.2%	17.1%	16.9%	16.1%
Return on capital employed %	—	25.8%	28.1%	26.2%	26.3%	25.7%	24.5%
Return on equity %	64.4%	21.2%	20.8%	20%	19.9%	19%	18.1%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
28 Sept 2026, 5:05 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
4 Sept 2026, 3:19 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
4 Sept 2026, 2:56 pm	Company Update General	Letter To Shareholders	PDF
3 Sept 2026, 12:54 pm	Others Business Responsibility and Sustainability Reporting (BRSR)	Business Responsibility and Sustainability Reporting (BRSR)	PDF
3 Sept 2026, 12:46 pm	AGM/EGM AGM	Notice Of The 35Th Annual General Meeting	PDF
3 Sept 2026, 12:37 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
2 Sept 2026, 5:11 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
1 Sept 2026, 6:04 pm	Company Update General	General Updates	PDF

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	42	68	66	87	269	337	272	311	432	523
	-6	-36	-69	-41	-8	-271	-218	-313	-335	-582
	-14	-7	-12	-33	-24	-41	-28	-38	-38	-46
Net cash flow	23	25	-14	13	236	25	26	-40	59	-106
Free cash flow	—	—	—	—	269	246	78	165	241	275
CFO / Operating profit %	—	—	34.1%	—	81.7%	85.3%	61.6%	56.4%	66.8%	68.8%

Caplin Point Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Segment results

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Announcements

Not in the F&O segment

25

1

1

Announcements

Annual reports

Investor Presentation and earnings call

Segment results

Compounded sales growth

Compounded profit growth

Return on equity

Rest of the World · revenue

Caplin Point Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Segment results

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Announcements

Ratio timeline

Not in the F&O segment

Dividends25

Board meetings1

Stock splits1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Investor Presentation and earnings call

Profit & loss

Balance sheet

Segment results

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Rest of the World · revenue

25

1

1